Metrics to compare | PA8 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPA8PeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −1.6x | −0.2x | |
PEG Ratio | 0.00 | 0.02 | 0.00 | |
Price/Book | 0.0x | 1.1x | 2.6x | |
Price / LTM Sales | 0.0x | 4.0x | 2.7x | |
Upside (Analyst Target) | - | 182.1% | 72.2% | |
Fair Value Upside | Unlock | 20.8% | 12.4% | Unlock |
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. Paion AG was founded in 2000 and is based in Aachen, Germany.